243 related articles for article (PubMed ID: 21865367)
1. Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules.
Li H; Robinson KA; Anton B; Saldanha IJ; Ladenson PW
J Clin Endocrinol Metab; 2011 Nov; 96(11):E1719-26. PubMed ID: 21865367
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach.
Vriens D; Adang EM; Netea-Maier RT; Smit JW; de Wilt JH; Oyen WJ; de Geus-Oei LF
J Clin Endocrinol Metab; 2014 Sep; 99(9):3263-74. PubMed ID: 24873995
[TBL] [Abstract][Full Text] [Related]
3. Selective use of Molecular Testing Based on Sonographic Features of Cytologically Indeterminate Thyroid Nodules: A Decision Analysis.
Zanocco KA; Wang MM; Yeh MW; Livhits MJ
World J Surg; 2020 Feb; 44(2):393-401. PubMed ID: 31538250
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of using a molecular diagnostic test to improve preoperative diagnosis of thyroid cancer.
Najafzadeh M; Marra CA; Lynd LD; Wiseman SM
Value Health; 2012 Dec; 15(8):1005-13. PubMed ID: 23244801
[TBL] [Abstract][Full Text] [Related]
5. Cost analysis of reflexive versus selective molecular testing for indeterminate thyroid nodules.
Hu QL; Schumm MA; Zanocco KA; Yeh MW; Livhits MJ; Wu JX
Surgery; 2022 Jan; 171(1):147-154. PubMed ID: 34284895
[TBL] [Abstract][Full Text] [Related]
6. Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis.
Cheung K; Roman SA; Wang TS; Walker HD; Sosa JA
J Clin Endocrinol Metab; 2008 Jun; 93(6):2173-80. PubMed ID: 18364376
[TBL] [Abstract][Full Text] [Related]
7. Molecular Testing for Thyroid Nodules of Indeterminate Cytology: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2022; 22(2):1-111. PubMed ID: 35591972
[TBL] [Abstract][Full Text] [Related]
8. Cost comparison of initial lobectomy versus fine-needle aspiration for diagnostic workup of thyroid nodules in children.
Baxter KJ; Short HL; Thakore MA; Fisher JG; Rothstein DH; Heiss KF; Raval MV
J Pediatr Surg; 2017 Sep; 52(9):1471-1474. PubMed ID: 28073489
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of molecular testing for thyroid nodules with atypia of undetermined significance cytology.
Lee L; How J; Tabah RJ; Mitmaker EJ
J Clin Endocrinol Metab; 2014 Aug; 99(8):2674-82. PubMed ID: 24684467
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of molecular testing for cytologically indeterminate thyroid nodules.
Dharampal N; Smith K; Harvey A; Paschke R; Rudmik L; Chandarana S
J Otolaryngol Head Neck Surg; 2022 Dec; 51(1):46. PubMed ID: 36544210
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Diagnostic Lobectomy Versus Observation for Thyroid Nodules >4 cm.
Lee L; Mitmaker EJ; Chabot JA; Lee JA; Kuo JH
Thyroid; 2016 Feb; 26(2):271-9. PubMed ID: 26715288
[TBL] [Abstract][Full Text] [Related]
12. Utility and cost-effectiveness of molecular testing in thyroid nodules with indeterminate cytology.
Labourier E
Clin Endocrinol (Oxf); 2016 Oct; 85(4):624-31. PubMed ID: 27155136
[TBL] [Abstract][Full Text] [Related]
13. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology.
Alexander EK; Kennedy GC; Baloch ZW; Cibas ES; Chudova D; Diggans J; Friedman L; Kloos RT; LiVolsi VA; Mandel SJ; Raab SS; Rosai J; Steward DL; Walsh PS; Wilde JI; Zeiger MA; Lanman RB; Haugen BR
N Engl J Med; 2012 Aug; 367(8):705-15. PubMed ID: 22731672
[TBL] [Abstract][Full Text] [Related]
14. Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the Afirma Gene Expression Classifier in cytologically indeterminate thyroid nodules?
Kloos RT; Reynolds JD; Walsh PS; Wilde JI; Tom EY; Pagan M; Barbacioru C; Chudova DI; Wong M; Friedman L; LiVolsi VA; Rosai J; Lanman RB; Kennedy GC
J Clin Endocrinol Metab; 2013 Apr; 98(4):E761-8. PubMed ID: 23476074
[TBL] [Abstract][Full Text] [Related]
15. Update on Molecular Testing for Cytologically Indeterminate Thyroid Nodules.
Nishino M; Nikiforova M
Arch Pathol Lab Med; 2018 Apr; 142(4):446-457. PubMed ID: 29336606
[TBL] [Abstract][Full Text] [Related]
16. Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules.
Patel KN; Angell TE; Babiarz J; Barth NM; Blevins T; Duh QY; Ghossein RA; Harrell RM; Huang J; Kennedy GC; Kim SY; Kloos RT; LiVolsi VA; Randolph GW; Sadow PM; Shanik MH; Sosa JA; Traweek ST; Walsh PS; Whitney D; Yeh MW; Ladenson PW
JAMA Surg; 2018 Sep; 153(9):817-824. PubMed ID: 29799911
[TBL] [Abstract][Full Text] [Related]
17. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
Witt RL
Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of lobectomy versus genetic testing (Afirma®) for indeterminate thyroid nodules: Considering the costs of surveillance.
Balentine CJ; Vanness DJ; Schneider DF
Surgery; 2018 Jan; 163(1):88-96. PubMed ID: 29128178
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of Gene Expression Classifier Testing of Indeterminate Thyroid Nodules Utilizing a Real Cohort Comparator.
Shapiro S; Pharaon M; Kellermeyer B
Otolaryngol Head Neck Surg; 2017 Oct; 157(4):596-601. PubMed ID: 28828911
[TBL] [Abstract][Full Text] [Related]
20. Molecular diagnostics for thyroid nodules: the current state of affairs.
Mon SY; Hodak SP
Endocrinol Metab Clin North Am; 2014 Jun; 43(2):345-65. PubMed ID: 24891166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
